Nemaura Medical Appoints Bashir Timol Chief Business Officer
April 09 2018 - 9:30AM
Business Wire
Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology
company developing the wireless sugarBEAT® non-invasive glucose
monitoring system for adjunctive use by persons with diabetes,
today announced that Bashir Timol, current Director of Strategy
& Corporate Development, has been named Chief Business Officer,
effective immediately.
In this newly-created position, Mr. Timol will oversee Nemaura
Medical’s corporate development and strategic planning. Mr. Timol
will continue to serve as a member of the Company’s Board of
Directors.
“Bashir has brought significant business expertise to Nemaura
Medical since our inception. As our Chief Business Officer, he can
provide critical leadership as the commercialization of sugarBEAT®
draws closer.” said Dr. Faz Chowdhury, Chief Executive Officer of
Nemaura.
About Nemaura Medical, Inc.
Nemaura Medical Inc. (NASDAQ: NMRD), is a medical technology
company developing sugarBEAT® as a non-invasive, affordable and
flexible glucose monitoring system for adjunctive use by persons
with diabetes. SugarBEAT® consists of a disposable adhesive
skin-patch connected to a rechargeable transmitter, with an app
displaying glucose readings. For more information, please visit
www.NemauraMedical.com and www.SugarBEAT.com.
Cautionary Statement Regarding Forward Looking
Statements
The statements in this press release that are not historical
facts, and may constitute forward-looking statements that are based
on current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, risks related to
regulatory approvals and the success of Nemaura Medical’s ongoing
studies, including the safety and efficacy of Nemaura Medical’s
sugarBEAT® system, the failure of future development and
preliminary marketing efforts, Nemaura Medical’s ability to secure
additional commercial partnering arrangements, risks and
uncertainties relating to Nemaura Medical and its partners’ ability
to develop, market and sell sugarBEAT®, the availability of
substantial additional equity or debt capital to support its
research, development and product commercialization activities, and
the success of its research, development, regulatory approval,
marketing and distribution plans and strategies, including those
plans and strategies related to sugarBEAT®. These and other risks
and uncertainties are identified and described in more detail in
Nemaura Medical’s filings with the Securities and Exchange
Commission, including, without limitation, its Annual Report on
Form 10-K for the current year, its Quarterly Reports on Form 10-Q,
and its Current Reports on Form 8-K. Nemaura Medical undertakes no
obligation to publicly update or revise any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180409005764/en/
Nemaura MedicalBashir TimolChief Business
Officerbashir.timol@nemauramedical.comorThe Ruth GroupLee
Roth646-536-7012lroth@theruthgroup.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Apr 2023 to Apr 2024